BHP Attracts AI-Focused Investors as Copper Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
AUSTIN, Texas, May 03, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Monday, May 14th @ 4:30pm Eastern Time | |||
| Domestic: | 800-239-9838 | ||
| International: | 323-794-2551 | ||
| Conference ID: | 5200441 | ||
| Webcast: | http://public.viavid.com/index.php?id=129615 | ||
| Replays, Available through May 28: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 5200441 | ||
About Vermillion
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
[email protected]
